Blood Pressure Control and Associated Factors among Hypertension Comorbid Type 2 Diabetic Patients in Southeast Ethiopia
CONCLUSION: Uncontrolled hypertension was found to be high among hypertension comorbid type 2 diabetic patients. Patients' adherence to antihypertensive medication, physical activity, and alcohol abstinence should be maximized. Loss of weight is also crucial, as is the early detection and management of comorbidities.PMID:38655153 | PMC:PMC11039015 | DOI:10.1155/2024/6668436 (Source: International Journal of Hypertension)
Source: International Journal of Hypertension - April 24, 2024 Category: Cardiology Authors: Fikreab Desta Selamawit Mengesha Fanuel Belayneh Demelash Woldeyohannes Yohannes Tekalegn Demisu Zenbaba Biniyam Sahiledengle Dejene Hailu Source Type: research
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
CONCLUSIONS: Within this specific population, GLP-1 RAs exhibit a notable association with substantial reductions in HbA1c, FBG, and body weight. The administration of these medications is concurrent with an elevated incidence of side effects, which are predominantly gastrointestinal and tolerable.TRIAL REGISTRATION: PROSPERO identifier: CRD42023393020.PMID:38659064 | DOI:10.1186/s13098-024-01337-5 (Source: Atherosclerosis)
Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Louise Buonalumi Tacito Yugar Luis Gustavo Sedenho-Prado Isadora Maria Castilho da Silva Ferreira Cleide Aparecida Moreira Silva Andrei C Sposito Cintia Cercato Source Type: research
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
CONCLUSIONS: Patients with T2DM and atherosclerosis are at high risk of limb events. Ticagrelor decreased this risk, but increased bleeding. Future trials evaluating the combination of ticagrelor and aspirin would further elucidate the benefit/risk of such therapy in patients with PAD, including those without coronary artery disease. (A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus [THEMIS]: NCT01991795).PMID:38658101 | DOI:10.1016/j.jacc.2024.03.377 (Source: Atherosclerosis)
Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Marc P Bonaca Deepak L Bhatt Tabassome Simon Kim Michael Fox Shamir Mehta Robert A Harrington Lawrence A Leiter Warren H Capell Claes Held Anders Himmelmann Wilhelm Ridderstr åle Jersey Chen Jane J Lee Yang Song Marielle Andersson Jayne Prats Mikhail Kos Source Type: research
The predictive value of plasma uridine for type 2 diabetes and its atherosclerotic complications
CONCLUSIONS: Fasting uridine has potential as a predictor of diabetes. Δuridine is closely associated with carotid atherosclerosis in patients with T2D.PMID:38657664 | DOI:10.1530/EC-24-0075 (Source: Atherosclerosis)
Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Yueyuan Yang Tingting Yu Zhili Niu Ling Gao Source Type: research
Association of Water Arsenic With Incident Diabetes in U.S. Adults: The Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study
CONCLUSIONS: Low to moderate water arsenic levels (<10 µg/L) were associated with T2D incidence in the SHFS and MESA cohorts.PMID:38656975 | DOI:10.2337/dc23-2231 (Source: Atherosclerosis)
Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Maya Spaur Marta Galvez-Fernandez Qixuan Chen Melissa A Lombard Benjamin C Bostick Pam Factor-Litvak Amanda M Fretts Steven J Shea Ana Navas-Acien Anne E Nigra Source Type: research
1,25(OH)2D3 inhibits pancreatic stellate cells activation and promotes insulin secretion in T2DM
ConclusionOur findings identify that PSCs activation contributes to islet fibrosis and β-cell dysfunction. 1,25(OH)2D3 exerts beneficial effects on T2DM potentially by inhibiting PSCs activation and inflammatory response, highlighting promising control strategies of T2DM by vitamin D.Graphical AbstractFig. 7 Molecular mechanism of 1,25(OH)2D3 in β cell damage following PSCs activation in T2DM mice. (Source: Endocrine)
Source: Endocrine - April 24, 2024 Category: Endocrinology Source Type: research
Therapeutic patient education and treatment intensification of diabetes and hypertension in subjects with newly diagnosed type 2 diabetes mellitus: a longitudinal study
ConclusionsTPE, delivered as both individual and group sessions, represents an effective tool to reduce the need to intensify treatment of both diabetes and hypertension. Therefore, it can ensure better control of diabetes and hypertension with fewer medications. This could reduce adverse effects and costs and improve quality of life and medication taking in patients with type 2 diabetes. (Source: Endocrine)
Source: Endocrine - April 24, 2024 Category: Endocrinology Source Type: research
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial —Study Design and Protocol
AbstractIntroductionMultiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)
ConclusionsPhysicians should pay attention to side effects of SGLT2is to maintain the patients ’ QOL when SGLT2is are initiated or added-on. Add-on of luseogliflozin increased patients’ QOL more than DPP-4is. Considering patients’ QOL and treatment satisfaction is important for selecting SGLT2is or DPP-4is.Trial RegistrationUMIN000030128 and jRCTs031180241. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Glucagon-like peptide 1 receptor agonists have been proven to be effective in adults with diabetes and children with obesity. However, children with type 2 diabetes constitute an underrepresented subpopulation... (Source: Diabetology and Metabolic Syndrome)
Source: Diabetology and Metabolic Syndrome - April 24, 2024 Category: Endocrinology Authors: Louise Buonalumi Tacito Yugar, Luis Gustavo Sedenho-Prado, Isadora Maria Castilho da Silva Ferreira, Cleide Aparecida Moreira Silva, Andrei C. Sposito and Cintia Cercato Tags: Research Source Type: research
Polystyrene nanoplastics with different functional groups and charges have different impacts on type 2 diabetes
Increasing attention is being paid to the environmental and health impacts of nanoplastics (NPs) pollution. Exposure to nanoplastics (NPs) with different charges and functional groups may have different advers... (Source: Particle and Fibre Toxicology)
Source: Particle and Fibre Toxicology - April 24, 2024 Category: Toxicology Authors: Yunyi Wang, Ke Xu, Xiao Gao, Zhaolan Wei, Qi Han, Shuxin Wang, Wanting Du and Mingqing Chen Tags: Research Source Type: research
Association of 25-hydroxyvitamin D, lipoprotein-associated phospholipase A2 and asymptomatic coronary artery disease in patients with type 2 diabetes mellitus
To evaluate the relationship of 25-hydroxyvitamin D (25(OH)D), lipoprotein-associated phospholipase A2 (Lp-PLA2), and coronary artery disease (CAD) in type 2 diabetes mellitus (T2DM) patients with no history or symptoms of cardiovascular disease. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 24, 2024 Category: Endocrinology Authors: Qian Zhang, Qing-qing Zhang, Jiao-jiao He, Shu-qin Dong, Yu Lu Source Type: research
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services
Conclusions
This study offers reassurance in cases of inadvertent exposure to GLP1-RA during the first trimester of pregnancy. Due to the limited sample size, larger studies are required to validate these findings. (Source: BMJ Open)
Source: BMJ Open - April 24, 2024 Category: General Medicine Authors: Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simoes-Wüst, A. P., Addor, M.-C., Baud, D., Lamine, F., Panchaud, A., Tags: Open access, Pharmacology and therapeutics Source Type: research
Therapeutic patient education and treatment intensification of diabetes and hypertension in subjects with newly diagnosed type 2 diabetes mellitus: a longitudinal study
ConclusionsTPE, delivered as both individual and group sessions, represents an effective tool to reduce the need to intensify treatment of both diabetes and hypertension. Therefore, it can ensure better control of diabetes and hypertension with fewer medications. This could reduce adverse effects and costs and improve quality of life and medication taking in patients with type 2 diabetes. (Source: Endocrine)
Source: Endocrine - April 24, 2024 Category: Endocrinology Source Type: research
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)
ConclusionsPhysicians should pay attention to side effects of SGLT2is to maintain the patients ’ QOL when SGLT2is are initiated or added-on. Add-on of luseogliflozin increased patients’ QOL more than DPP-4is. Considering patients’ QOL and treatment satisfaction is important for selecting SGLT2is or DPP-4is.Trial RegistrationUMIN000030128 and jRCTs031180241. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
